Which SSRIs are known strong CYP2D6 inhibitors?

Fluoxetine and Paroxetine are both classified as selective serotonin reuptake inhibitors (SSRIs) that exhibit strong inhibition of the CYP2D6 enzyme. This is significant because CYP2D6 is responsible for metabolizing a variety of medications, and when these SSRIs inhibit this enzyme, they can lead to increased plasma concentrations of drugs that are substrates of CYP2D6. This can enhance the effects or side effects of those medications, necessitating careful consideration in clinical practice for patients who are taking multiple medications.

Fluoxetine, in particular, is known for its long half-life and robust inhibition of CYP2D6, while Paroxetine has a shorter half-life but is also a potent inhibitor. Understanding the impact of these SSRIs on the CYP2D6 pathway is crucial for managing potential drug interactions and ensuring patient safety in treatment regimens.